Posted by Michael Wonder on 03 Nov 2025
US FDA approves Kygevvi (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency
3 November 2025 - UCB today announced that Kygevvi has been granted approval by the US FDA for the treatment of adults and paediatric patients living with thymidine kinase 2 deficiency, with an age of symptom onset on or before 12 years.
It is the first and only approved treatment for these patients living with thymidine kinase 2 deficiency.
